Jaka jest cena za EFFECTOR Therapeutics, Inc. (EFTRW)

Cena za EFFECTOR Therapeutics, Inc. (EFTRW) wynosi $0.0006

Jaka jest kapitalizacja rynkowa dla EFFECTOR Therapeutics, Inc. (EFTRW)

Kapitalizacja rynkowa dla EFFECTOR Therapeutics, Inc. (EFTRW) wynosi $2.82K

EFFECTOR Therapeutics, Inc. (EFTRW) Wskaźnik C/Z

eFFECTOR Therapeutics, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective translation regulator inhibitors aimed at combating cancer. Their primary investigational drug, Tomivosertib, is an orally administered small-molecule MNK inhibitor currently undergoing Phase 2b clinical trials. This candidate is being evaluated for its efficacy in patients suffering from metastatic non-small cell lung cancer. Additionally, the company is advancing zotatifin, another small molecule engineered to block eukaryotic initiation factor 4A (eIF4E). Zotatifin is presently in Phase 1/2 clinical studies for individuals with various solid tumors. Furthermore, it's being tested in a Phase 2a open-label expansion cohort, in conjunction with fulvestrant and abemaciclib, for patients afflicted with ER-positive breast cancer. eFFECTOR Therapeutics, Inc. also holds a research collaboration and licensing pact with Pfizer Inc., focused on co-developing eIF4E inhibitors. Established in 2012, the company maintains its corporate headquarters in Solana Beach, California.

Rok	Wskaźnik P/E	Zmień
Za mało danych dla podanych dat.

Rok

Wskaźnik P/E

Zmień

Za mało danych dla podanych dat.

Firma	Wskaźnik P/E	Różnica wskaźnika P/E	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	28.05	-	US
Argenx SE ARGX.US	31.14	-	NL
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	19.30	-	BE
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR

Firma

Wskaźnik P/E

Różnica wskaźnika P/E

Kraj